Gohari Sharon, Gambla Charles, Healey Mary, Spaulding Gail, Gordon Kenneth B, Swan James, Cook Brian, West Dennis P, Lapiere Jean-Christophe
Department of Dermatology, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Dermatol Surg. 2002 Dec;28(12):1107-14; discussion 1114. doi: 10.1046/j.1524-4725.2002.02130.x.
Human Skin Substitute (Apligraf, Organogenesis, Inc., Canton, MA) is a bi-layered tissue-engineered living biological dressing developed from neonatal foreskin. It consists of a bovine collagen matrix containing human fibroblasts with an overlying sheet of stratified human epithelium containing living human keratinocytes. Human Skin Substitute (HSS) appears to be immunologically inert, and has shown usefulness in the treatment of chronic and acute wounds.
Primary objectives were to evaluate the safety and efficacy of HSS in the treatment of full-thickness wounds in a prospective case series. Secondary objectives were to determine the rate of complete wound reepithelialization, incidence of complete wound healing, pain at wound site, overall cosmetic outcome, and patient satisfaction.
Fourteen patients were enrolled in the study, of which 12 were evaluable. HSS was applied in a blinded fashion to 6 of the patients immediately following Mohs or excisional surgery for skin cancer. The remaining 6 patients were allowed to heal by secondary intention. Both groups were evaluated at weekly appointments until complete reepithelialization occurred. During each evaluation, wound quality was assessed through the Vancouver Burn Scar Assessment Scale by the investigator and an independent blinded dermatologist. The investigator, blinded observer, and patient further evaluated the cosmetic outcome of the wound through the use of a Visual Analog Scale over a 6-month period.
HSS patients and secondary intention patients were equivalent in comorbid factors such as pain, erythema, edema, exudate, infection, or hematoma between the groups. The incidence of complete wound healing at 6 months was 100% for both groups. Both groups also appeared to heal at similar rates, as defined by the complete reepithelialization of the wound. HSS patients ultimately resulted in more pliable and less vascular wounds as defined by the Vancouver Burn Scar Assessment Scale. Patient satisfaction with cosmetic outcome in both groups was positive at 6 months.
HSS appears to be a safe, well-tolerated biological dressing with equivalent comorbid factors to secondary intention healing. HSS, however, seems to produce a more pliable and less vascular scar than those developed through healing by secondary intention. HSS also appears to produce more satisfactory cosmetic results when compared to secondary intention healing.
人皮肤替代物(Apligraf,Organogenesis公司,马萨诸塞州坎顿)是一种由新生儿包皮开发的双层组织工程化活性生物敷料。它由含有人类成纤维细胞的牛胶原蛋白基质和覆盖有含活人类角质形成细胞的分层人类上皮细胞片组成。人皮肤替代物(HSS)似乎在免疫上是惰性的,并且已显示在治疗慢性和急性伤口方面有用。
主要目的是在前瞻性病例系列中评估HSS治疗全层伤口的安全性和有效性。次要目的是确定伤口完全再上皮化的速率、完全伤口愈合的发生率、伤口部位的疼痛、总体美容效果和患者满意度。
14名患者纳入研究,其中12名可评估。在Mohs手术或皮肤癌切除术后,HSS以盲法应用于6名患者。其余6名患者采用二期愈合。两组患者每周进行评估,直至伤口完全再上皮化。在每次评估期间,研究者和一名独立的盲法皮肤科医生通过温哥华烧伤瘢痕评估量表评估伤口质量。研究者、盲法观察者和患者在6个月期间通过视觉模拟量表进一步评估伤口的美容效果。
HSS组患者和二期愈合组患者在疼痛、红斑、水肿、渗出物、感染或血肿等合并症因素方面相当。两组在6个月时完全伤口愈合的发生率均为100%。根据伤口完全再上皮化的定义,两组的愈合速度似乎也相似。根据温哥华烧伤瘢痕评估量表,HSS组患者最终形成的伤口更柔软,血管化程度更低。两组患者在6个月时对美容效果的满意度均为阳性。
HSS似乎是一种安全、耐受性良好的生物敷料,其合并症因素与二期愈合相当。然而,与二期愈合形成的瘢痕相比,HSS似乎能产生更柔软、血管化程度更低的瘢痕。与二期愈合相比,HSS似乎也能产生更令人满意的美容效果。